20-F: Meihua International Medical Technologies Reports Fiscal Year 2023 Results

Meihua International Medical Technologies Co., Ltd. reports a decrease in revenue but an increase in net income for the fiscal year ended December 31, 2023, while also disclosing a material weakness in internal controls.

Summary

• Meihua International Medical Technologies Co., Ltd. reported total revenues of $97.10 million for the year ended December 31, 2023, a decrease of 6% compared to $103.35 million in 2022.
• Net income increased by 87.6% to $11.59 million in 2023 from $6.18 million in 2022.
• The company identified a material weakness in its internal control over financial reporting related to a lack of sufficient U.S. GAAP and SEC reporting knowledge among accounting personnel.
• Meihua is implementing remedial measures to address the material weakness, including hiring consultants and qualified accounting personnel.
• The company is also expanding into high-quality consumables and technology-based household products.
• The company has a diversified customer base with 4,981 customers as of December 31, 2023.
• The company is subject to various legal and operational risks and uncertainties as a company with its principal subsidiaries based in and primarily operating in China.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While net income increased, revenue decreased and a material weakness in internal controls was identified. The company is taking steps to address the weakness and expand into new product areas.

Positives

• Net income increased significantly in 2023.
• The company is taking steps to remediate the identified material weakness in internal controls.
• The company is expanding into new product areas.
• The company has a diversified customer base.

Negatives

• Revenue decreased in 2023.
• A material weakness in internal control over financial reporting was identified.
• The company is not presently in compliance with the continued listing requirements for The Nasdaq Stock Market.

Risks

• The company faces various legal and operational risks and uncertainties as a company with its principal subsidiaries based in and primarily operating in China.
• The company may be subject to intellectual property infringement claims.
• The company may not be able to prevent others from the unauthorized use of our intellectual property, which could materially harm our business and competitive position.
• Changes in U.S. and international trade policies, particularly with regard to China, may adversely impact our business and operating results.
• The market price for our Ordinary Shares may be volatile.
• The trading market for our Ordinary Shares will depend in part on the research and reports that securities or industry analysts publish about us or our business.
• Raising additional capital and the sale of additional Ordinary Shares or other equity securities could result in dilution to our shareholders, while the incurrence of debt may impose restrictions on our operations.
• Techniques employed by short sellers may drive down the market price of our Ordinary Shares.
• U.S. regulatory bodies may be limited in their ability to conduct investigations or inspections of our operations in the PRC.
• If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders.

Future Outlook

The company anticipates that its financial performance will continue to improve in 2024 and is actively transforming and expanding into high-quality consumables and technology-based household products.

Industry Context

The medical device industry is intensely competitive and subject to rapid change, with competition from both large, well-capitalized companies and smaller, specialized firms.

Comparison to Industry Standards

• The company competes with Shandong Weigao Group Medical Polymer Co., Limited, Jiangxi Hongda Medical Equipment Group Ltd., Henan Tuoren Medical Device Co., Ltd., Allmed Medical Products Co., Ltd., Jiangxi Sanxin Medtec Co., Ltd., and Jiangxi 3L Products Group Co., Ltd.
• These companies are competitors as well as partners.
• The company's revenues accounted for approximately 10% of the total revenues generated from all medical device manufactures in Touqiao Town.

Legal Proceedings

• A legal proceeding, Zhu Cheng v. Jiangsu Yada Technology Group Co., Ltd., Yangzhou Huada Medical Equipment Co., Ltd., Jiangsu Huadong Medical Equipment Industrial Co., Ltd., and Rehabilitation International Medical Co., Ltd. [Case No.: (2023) Su 1091 Minchu No. 1779], was filed with the Yangzhou Economic and Technological Development Zone Peoples Court.

Related Party Transactions

• The company sells products at market price to Yangzhou Meihua Import and Export Co., Ltd., an affiliate controlled by Kai Liu, the son of Yongjun Liu, our Chairman and shareholder.
• The company sells products at market price to Shanghai Xinya Pharmaceutical Hanjiang Co., Ltd., an affiliate controlled by Kai Liu, the son of Yongjun Liu, our Chairman and shareholder.
• On December 19, 2023, Huadong signed a letter of intent with Ms. Liu Fang to purchase 40% equity interest of Jiangsu Guomai Medical Equipment Co., Ltd (Guomai).

Stakeholder Impact

• Shareholders may experience dilution from the issuance of convertible notes and warrants.
• Investors may be deprived of the benefits of PCAOB inspections if the PCAOB is unable to inspect or investigate our auditor completely.
• The delisting of our securities, or the threat of their being delisted, may materially and adversely affect the value of your investment.

Next Steps

• The company intends to use the net proceeds from the convertible notes and warrants offering for general working capital purposes.
• The company plans to establish the Cybersecurity Incident Management and Emergency Response System (System) within three months.
• The company plans to take remedial measures including (i) hiring more qualified accounting personnel with relevant U.S. GAAP and SEC reporting experience and qualifications to strengthen the financial reporting function and to set up a financial and system control framework; (ii) implementing regular and continuous U.S. GAAP accounting and financial reporting training programs for our accounting and financial reporting personnel; and (iii) setting up an internal audit function as well as engaging an external consulting firm to assist us with assessment of Sarbanes-Oxley compliance requirements and improvement of overall internal control.

Key Dates

Keywords

medical devices, financial results, internal control, revenue, net income, China, Meihua International